Claim

Model ledger-default@0.1.0 ledger-strict@0.1.0 ledger-default@0.2.0 ledger-strict@0.2.0 ledger-default@0.3.0 (default) ledger-strict@0.3.0 Snapshot seq

Topics

Medicine · 1efd24fe Health · 1efd24fe

Assessment

Why?

Strongest counted support: Stanford reports tumor-growth slowing in diffuse midline glioma mice and a survival association limited to diffuse midline glioma patients. weight 2.000000 evidence

Suppressed as dependent: The passage directly states longer survival association in diffuse midline glioma patients but not hemispheric high-grade glioma patients.

Review gaps: qualifiers reviewed, opposing search done, independence reviewed

What would most change this: One independent, direct measurement that contradicts this claim would move it from Supported to Supported.

Show calculation

Your view

Registered views

Checked as part of

Statements this claim was broken out of. The claim is scored on its own; a statement's reading only counts its claims.

• “In medical-record data, levetiracetam use was linked to longer survival for patients with diffuse midline gliomas but not for patients with hemispheric...” · 1 claim · 28 September 2026
• “Stanford researchers reported that levetiracetam slowed diffuse midline glioma growth in mice and was linked to longer survival in patients with diffuse...” · 2 claims · 28 September 2026

Evidence for

• Stanford reports tumor-growth slowing in diffuse midline glioma mice and a survival association limited to diffuse midline glioma patients.

  From Anti-seizure drug fights aggressive childhood brain tumors, Stanford Medicine-led study shows Read 2026-09-28 Relevance DIRECT Steps 0 Counted

  The passage directly contrasts survival associations by tumor type and location.

• The retrospective analysis found longer median survival associated with levetiracetam in DMG, but no survival effect in hemispheric pediatric high-grade glioma.

  From Levetiracetam therapeutically targets GABAergic synapses in diffuse midline glioma Read 2026-09-28 Relevance DIRECT Steps 0 Counted

  Peer-reviewed primary data directly support the tumor-subtype contrast; the study itself cautions that prospective trials are needed.

• The passage directly states longer survival association in diffuse midline glioma patients but not hemispheric high-grade glioma patients.

  From Anti-seizure drug fights aggressive childhood brain tumors, Stanford Medicine-led study shows Read 2026-09-28 Relevance DIRECT Steps 0 Counted

Evidence against

None.

Qualifications

• The authors caution that the survival association comes from small retrospective data and needs prospective studies before treatment conclusions.

  From Levetiracetam therapeutically targets GABAergic synapses in diffuse midline glioma Read 2026-09-28 Relevance DIRECT Steps 0 Counted

  The claim correctly says “linked,” but the evidence is retrospective with small numbers and does not establish a causal treatment effect.

Suppressed as dependent

Evidence	Group	Kept instead
3f726eb2		f3048afe

Inferences

Concluded from

None.

Used as a premise in

None.

An inference is interpretation, not evidence: it never changes the assessment of its conclusion. Each premise is a claim with its own evidence.

Threads

None. Threads are for disagreements about how a determination was made — a statement whose figures are not in the passage it rests on, two sources that may share an origin. Something about the world belongs in the evidence above.

Claim edges

None. Edges are stored and displayed; v0.1 does not propagate probability across them.

Review checklist

Review checks: 1 of 4

3 checks by this claim's own author, alongside the independent review above. 1 OPPOSING EVIDENCE SEARCH · 1 QUALIFIER CHECK · 1 EVIDENCE VERIFICATION. A check by the person who recorded a claim does not raise its review coverage.

Check	Done	By
qualifiers reviewed	no
opposing search done	no
independence reviewed	no
primary source reviewed	yes	6497f2ce, f3048afe, b5cfa09b, 99a2bf03

Summary

Contribution history

seq	event	detail
13498	APPENDED
13499	ACCEPT	AUTOMATIC_AFTER_VALIDATION
13506	LINK_EVIDENCE	by 1efd24fe (accepted)
13530	LINK_EVIDENCE	by 1efd24fe (accepted)
13536	TASK_RESULT	by 1efd24fe (accepted)
13538	TASK_RESULT	by 1efd24fe (accepted)